Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei Zhou
Caicun Zhou

Showing results (1-10 of 1,917) with videos related to

Pageof 192
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Notch Mutations as a Novel Biomarker for ImmunotherapyFei Zhou, Caicun Zhou
The Lancet. Oncology|February 22, 2015
Necitumumab for patients with non-squamous NSCLC: uninspiring resultsFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2021
Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase InhibitorsFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: ReplyFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a SprintFei Zhou, Caicun Zhou
Translational Lung Cancer Research|September 19, 2018
Lung cancer in never smokers-the East Asian experienceFei Zhou, Caicun Zhou
Cellular & Molecular Immunology|November 12, 2020
The cutting-edge progress of immune-checkpoint blockade in lung cancerFei Zhou, Meng Qiao, Caicun Zhou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drugFei Zhou, Xiaoxia Chen, Caicun Zhou
Oncotargets and Therapy|March 11, 2014
Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsWei Li, Fei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?Fei Zhou, Xiaoxia Chen, Caicun Zhou
Pageof 192

Showing results (1-10 of 1,917) with videos related to

Sort By:
Pageof 192
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
Notch Mutations as a Novel Biomarker for ImmunotherapyFei Zhou, Caicun Zhou
The Lancet. Oncology|February 22, 2015
Necitumumab for patients with non-squamous NSCLC: uninspiring resultsFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2021
Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase InhibitorsFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: ReplyFei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a SprintFei Zhou, Caicun Zhou
Translational Lung Cancer Research|September 19, 2018
Lung cancer in never smokers-the East Asian experienceFei Zhou, Caicun Zhou
Cellular & Molecular Immunology|November 12, 2020
The cutting-edge progress of immune-checkpoint blockade in lung cancerFei Zhou, Meng Qiao, Caicun Zhou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drugFei Zhou, Xiaoxia Chen, Caicun Zhou
Oncotargets and Therapy|March 11, 2014
Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsWei Li, Fei Zhou, Caicun Zhou
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?Fei Zhou, Xiaoxia Chen, Caicun Zhou
Pageof 192